7.80
-3.70%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pharmigene
Its shares trade on Taipei Exchange under the ticker 7595.TWO. It has been listed since 22 December 2020. In the fiscal year to 31 December 2025, it reported revenue of TWD 199.9m and a net loss of TWD 73.0m. At that date it held total assets of TWD 988.4m and shareholders' equity of TWD 278.4m.
Pharmigene, Inc. engages in the manufacturing and sales of pharmaceutical genetic diagnostic products. The company is headquartered in Taipei City, Taipei. The company went IPO on 2020-12-22. The firm mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The firm's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The firm mainly distributes its products in Taiwan market and other markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Dec 2020
- Website
- pharmigene.com.tw ↗
Leadership
Pay as last reported
- Ms. Fuhui ZhanChairman of the Board, General Manager, since 2019
- Mr. Guanzhi ChenChief Operating Officer, Director, since 2019
- Mr. Yichen LiuDeputy General Manager-Development & Manufacturing Division
- Jiaru XuDeputy General Manager-Market Business Group
- Yishan LuoHead of Accounting
- Shichen CaiDirector
- Mr. Junyi LiDirector
- Mr. Ce XiaoDirector
- Mr. Yingzhou XuDirector
- Mr. Chiping ChenIndependent Director
- Ms. Yirou ChenIndependent Director
- Mr. Yi-Shyon ChenIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Taipei City, Taiwan, with a focus on biotechnology and health care sector.
- Offers a range of molecular diagnostic products including AutoEx16 and various genetic test kits.
- Provides drug genetic testing and personalized genetic testing services in the precision medicine field.
Weaknesses
- Limited market presence as products are mainly distributed in the Taiwan market.
- Reliance on a single market (Taiwan) for product distribution may pose risks.
- No mention of international expansion or diversification strategies in the provided information.
Opportunities
- Potential to expand into international markets beyond Taiwan for product distribution.
- Growing demand for precision medicine and genetic testing services globally.
- Opportunity to develop new diagnostic kits and testing technologies for emerging markets.
Threats
- Competition from other biotechnology firms in the precision medicine sector.
- Regulatory challenges in the health care and biotechnology industries.
- Dependence on the Taiwan market could be affected by regional economic or political changes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.